| TF Name |
Cell-line |
Condition/Source |
Collections |
Species |
Identifiers |
JASPAR ID |
| CTCF |
CD34+ hematopoietic stem cells-derived proerythroblasts |
2-trimester fetal liver |
Permissive
Robust
|
Homo sapiens |
GSE36985
...
|
MA0139.1
|
| CTCF |
CD34+ hematopoietic stem cells-derived proerythroblasts |
adult bone marrow |
Permissive
|
Homo sapiens |
GSE36985
...
|
MA0139.1
|
| CTCF |
HCT-116 (colon carcinoma) |
DNMT1KO |
Permissive
Robust
|
Homo sapiens |
GSE50610
...
|
MA0139.1
|
| CTCF |
HCT-116 (colon carcinoma) |
DNMT3BKO |
Permissive
Robust
|
Homo sapiens |
GSE50610
...
|
MA0139.1
|
| CTCF |
HCT-116 (colon carcinoma) |
No special treatment |
Permissive
Robust
|
Homo sapiens |
GSE50610
...
|
MA0139.1
|
| CTCF |
HCT-116 (colon carcinoma) |
DNMT1KO, DNMT3BKO |
Permissive
Robust
|
Homo sapiens |
GSE50610
...
|
MA0139.1
|
| CTCF |
K562 (myelogenous leukemia) |
5-aza-2’-deoxycytidine (decitabine; Sigma, A3656) dissolved in DMSO to 10mM. Drug was administered at 1uM daily for 3 days. Control K562 cells were mock treated with DMSO. |
Permissive
Robust
|
Homo sapiens |
GSE50610
...
|
MA0139.1
|
| CTCF |
K562 (myelogenous leukemia) |
none |
Permissive
Robust
|
Homo sapiens |
GSE50611
...
|
MA0139.1
|
| CTCF |
erythroid progenitors |
none |
Permissive
Robust
|
Homo sapiens |
GSE52637
...
|
MA0139.1
|
| CTCF |
T47D (invasive ductal carcinoma) |
unstimulated |
Permissive
Robust
|
Homo sapiens |
GSE53463
...
|
MA0139.1
|
Showing 10 records in page 4
from 97 pages